REPORT FROM THE ANNUAL GENERAL MEETING IN BIOARCTIC AB (PUBL)

BioArctic AB (publ) held its Annual General Meeting on Tuesday May 15, 2018. The following resolutions were adopted:

Annual report and result
The meeting adopted the income statement and balance sheet for the Company and for the Group according to submitted accounting documents and resolved, in accordance with the Board of Directors’ proposal, that profits of SEK 613,962,462 be carried forward. No dividends to shareholders are paid.

Discharge from liability
The Annual General Meeting granted the Board of Directors and the Chief Executive Officer discharge from liability for the financial year 2017.

Board members and fees
The ordinary board members Wenche Rolfsen, Ivar Verner, Hans Ekelund, Pär Gellerfors, Lars Lannfelt and Eugen Steiner were re-elected by the Annual General Meeting. Mikael Smedeby was elected new member of the board. Wenche Rolfsen and Ivar Verner were re-elected as Chairman and Deputy Chairman, respectively.

The meeting adopted the Nomination Committee’s proposal for board fees and other fees, with the following distribution: SEK 500,000 to the Chairman of the Board, SEK 250,000 to the Deputy Chairman, SEK 200,000 to each of the other board members not employed by the Company, SEK 100,000 to the Chairman of the Audit Committee, SEK 60,000 to each of the other members of the Audit Committee not employed by the Company, SEK 60,000 to the Chairman of the Remuneration Committee, and SEK 40,000 to each of the other members of the Remuneration Committee not employed by the Company.

Auditor and auditor fees
The meeting resolved, in accordance with the Nomination Committee’s proposal, to appoint the registered auditing firm Grant Thornton Sweden AB to be the auditor of BioArctic AB for the period until the end of the next Annual General Meeting. Fees to the auditor shall be paid upon approved account.

Remuneration to senior executives
The Annual General Meeting approved the Board of Directors’ proposal for resolution concerning guidelines for remuneration to senior executives.

Nomination Committee
The Nomination Committee’s proposal for principles for and the establishment of the Nomination Committee in preparation for the Annual General Meeting 2019 were approved by the meeting.

For further information, please contact:
Gunilla Osswald, CEO, gunilla.osswald@bioarctic.se, telephone + 46 (0)8 695 69 30
Jan Mattsson, CFO, jan.mattsson@bioarctic.se, telephone + 46 (0)703 52 27 72

About BioArctic
BioArctic AB (publ) is a Swedish research based biopharma company focusing on disease modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. The company also develops a potential treatment for Complete Spinal Cord Injury. BioArctic focuses on innovative treatments in areas with high unmet medical needs. Collaborations with universities are of great importance to the company together with our strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market and out-licensing potential.
BioArctic’s B-share is listed on Nasdaq Stockholm Mid Cap (Nasdaq Stockholm: BIOA B).
www.bioarctic.com 

The information was submitted for publication at 08:00 p.m. CET on May 15, 2018. 

Tags:

About Us

BioArctic AB is a Swedish research based biopharma company focusing on disease modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. The company also develops a potential treatment for Complete Spinal Cord Injury. BioArctic focuses on innovative treatments in areas with high unmet medical needs. Collaborations with universities are of great importance to the company together with our strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market- and out-licensing potential. www.bioarctic.se

Subscribe

Documents & Links